BMAC – Biopharmaceutical Manufacturer's Advisory Council
An initiative by leading Biopharmaceutical companies in the world to establish Singapore as the country of choice for global biomedical sciences manufacturing.
Takeda has made environmental efforts and its commitment to carbon zero by 2040 a priority. To date, Takeda has achieved carbon neutrality in our value chain for FY 2019. Click here to learn more about where Takeda’s emissions come from and its global carbon footprint.
Takeda’s first zero carbon energy building and the first in Singapore’s pharmaceutical industry the Manufacturing Support Building; has achieved Temporary Occupation Permit (TOP) in Sep 2022
Our R&D engine has produced exciting new molecular entities (NMEs) across our core Therapeutic Areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology.
At Takeda Singapore Manufacturing site, the Training Dept has AR (Augmented Reality) for an immersive training experience to enhance our people’s capability.